Funding for this research was provided by:
Krebsliga Schweiz (KLS-5112-08-2020)
B. Braun-Stiftung (BBST-D-20-00009)
National Institutes of Health (TL1 TR001871)
Received: 2 April 2023
Accepted: 24 July 2023
First Online: 2 August 2023
: A portion of this work was presented as oral presentation at the Clinical Congress 2022 of the American College of Surgeons (ACS) in San Diego, California from October 16–20, 2022.CESQIP and the hospitals participating in CESQIP are the source of the data used herein; they have not verified and are not responsible for the statistical validity of the data analysis or the conclusions derived by the authors. The conclusions, findings, and opinions expressed by the authors do not necessarily reflect the official position of the AAES or CESQIP. Use of CESQIP data does not imply endorsement by any of the groups named above.
: The study was performed in accordance with the Declaration of Helsinki. All methods were carried out in accordance with relevant guidelines and regulations. Waiver for ethical approval of this study was given by the Institutional Review Board of the University of California, San Francisco. Because of the use of de-identified data, the need for informed consent for participation was waived by the Institutional Review Board of the University of California, San Francisco.
: Not applicable.
: Julie Ann Sosa is a member of the Data Monitoring Committee of the Medullary Thyroid Cancer Consortium Registry supported by Novo Nordisk, Astra Zeneca, and Eli Lilly. Institutional research funding is received from Exelixis and Eli Lilly. All other authors declare no conflicts of interest.